Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

Results

Save Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

Clinical Trial	Phase	Eligible Participant	Official Title	Drugs in Trial	Location
NCT03038100	III	Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)	A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Utah, Virginia, Washington, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Bevacizumab anti-VEGF monoclonal antibody, Avastin, immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain VEGF antagonist Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03180307	III	Newly diagnosed stage III ovarian cancer	A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer	View Drugs	California, Florida, Minnesota, Ohio, Pennsylvania
Drug(s) in Trial Other Drug Names Main Known Action OTL38 fluorescent imaging ligand OTL38 Folate receptor imaging agent
NCT02122185	II	Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)	A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer	View Drugs	Alabama, California, Illinois, Minnesota
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Docetaxel Taxotere Microtubule stabilizer/mitotic inhibitor Metformin Fortamet, Glucophage, Glumetza, Riomet AMP-activated protein kinase (AMPK) activator Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02437812	II	Newly diagnosed stage II-IV ovarian cancer	A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma	View Drugs	California
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Metformin Fortamet, Glucophage, Glumetza, Riomet AMP-activated protein kinase (AMPK) activator Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02520154	II	Newly diagnosed stage III/IV high grade non-mucinous ovarian epithelial cancer (neo-adjuvant)	Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02834975	II	Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)	Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy	View Drugs	Florida
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT02766582	II	Newly diagnosed stage III/IV ovarian cancer after suboptimal debulking surgery	Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer	View Drugs	Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Pembrolizumab KEYTRUDA, MK3475, SCH 900475, Lambrolizumab Blocks PD-L1/2 inhibition of T cells
NCT03206645	Ib	Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)	Phase IB Study of Weekly Paclitaxel + Carboplatin With the BMI-1 Inhibitor PTC596 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy	View Drugs	Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor PTC596 polycomb ring finger oncogene inhibitor PTC596, BMI1 inhibitor PTC596 BMI1 inhibitor
NCT03206177	Ib	Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma	Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary	View Drugs	Oklahoma
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Galunisertib LY2157299 TGFBR1 antagonist Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02713386	I/II	Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)	A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	Illinois, Iowa, Maryland, Ohio, Oklahoma, Pennsylvania, Rhode Island, Virginia, Wisconsin
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor Ruxolitinib oral JAK inhibitor INCB18424, oral Janus-associated kinase inhibitor INCB18424, Jakafi, INCB18424 JAK1/2 kinase inhibitor
NCT02726997	I/II	Newly diagnosed stage III/IV high grade non-mucinous epithelial ovarian cancer	Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)	View Drugs	Texas
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Durvalumab MEDI4736, Anti-B7H1 Monoclonal Antibody MEDI4736, Imfinzi Blocks PD-L1 inhibition of T cells Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT03394885	I/II	Newly diagnosed stage III-IV ovarian cancer (neo-adjuvant; inc expansion)	Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer	View Drugs	North Carolina
Drug(s) in Trial Other Drug Names Main Known Action Atezolizumab RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq Blocks PD-L1 inhibition of T cells Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor
NCT02933073	I	Newly diagnosed stage III/IV ovarian cancer in remission after primary treatment or after secondary debulking of recurrence >12 months after last platinum	A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma	View Drugs	Connecticut
Drug(s) in Trial Other Drug Names Main Known Action OncoImmunome Anti-tumor immune response
NCT03245892	I	Newly diagnosed suspected stage III/IV high grade serous ovarian cancer (neo-adjuvant)	A Pilot Study of Nivolumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	View Drugs	New York
Drug(s) in Trial Other Drug Names Main Known Action Carboplatin Paraplat, Paraplatin, CBDCA, Blastocarb, Carboplat, Carbosin, Carbosol, Carbotec, Displata, Ercar, Nealorin, Novoplatinum, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo DNA damaging agent Nivolumab Anti-PD-1 human mab MDX-1106, MDX-1106, ONO-4538, Opdivo, BMS-936558 Blocks PD-L1/2 inhibition of T cells Paclitaxel Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL Microtubule stabilizer/mitotic inhibitor